Publications

5600 Results

Alliance trial A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas

Authors
M Katz;Q Shi;J Meyers;J Herman;M Chuong;B Wolpin;S Ahmad;R Marsh;L Schwartz;S Behr;W Frankel;E Collisson;J Leenstra;A Venook;J Meyerhardt;E O'Reilly
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), oral
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021501

Immunologic Predictors of Therapeutic Response to Neoadjuvant Therapy for Pancreatic Adenocarcinoma (PDA) in SWOG S1505

Authors
D Sohal;M Duong;R Chang;Y Xue;D Delman;I Garrido-Laguna;S Mulvihill;K Affolter;MK Washington;MS Beg;A Wang-Gillam;J Wade;N Gandhi;S Ahmad;A Lowy;EG Chiroean;K Guthrie;H Hochster;PA Philip;G Beatty
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 419); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), Poster Presentation and Poster Highlights session
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations

Authors
V Chung;K Guthrie;M Pishvaian;X Yu;A Lowy;EG Chiorean;M Duong;E O'Reilly;PA Philip
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr TPS447); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), poster session
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
S2001

Prognostic value of tumor deposits in stage III colon cancer patients, a post hoc analysis of CALGB/SWOG 80702 phase III study

Authors
R Cohen;Q Shi;J Meyers;Z Jin;M Svrcek;C Fuchs;F Couture;P Kuebler;J Bendell;P Kumar;D Lewis;B Tan;M Bertagnolli;H Hochster;C Blanke;E O'Reilly;A Shields;J Meyerhardt
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 10); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), rapid abstract presentation (oral)
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Discordance between central vs. local response assessments in neuroendocrine tumor (NET) patients enrolled in A021202

Authors
S Geyer;M Mahoney;T Asmis;N Hall;S Karovic;M Knopp;P Kumthekar;A Nixon;E O'Reilly;L Schwartz;J Strosberg;J Meyerhardt;M Maitland;E Bergsland
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr 361); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), poster
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021202

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)

Authors
M Overman;G Yothers;S Jacobs;H Sanoff;D Cohen;K Guthrie;NL Henry;P Ganz;ES Kopetz;P Lucas;CD Blanke;N Wolmark;H Hochster;T George;SMS Rocha Lima
Journal / Conference
J Clin Oncol 39, 2021 (suppl 3; abstr TPS158); ASCO GI Cancers Symposium (January 15-17, 2021, virtual), TIPS, poster
Year
2021
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/NRG-GI004

Predicting Severe Toxicities with Intensive Induction Chemotherapy for Adult Acute Myeloid Leukemia: Analysis of SWOG Trials S0106 and S1203

Authors
A Moseley;M Othus;G Garcia-Manero;F Appelbaum;H Erba;R Walter
Journal / Conference
Leukemia and Lymphoma Jul;62(7):1774-1777
Year
2021
Research Committee(s)
Leukemia
PMID
PMID33560164
PMC
PMC8282671
Study Number(s)
S0106, S1203

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation [Care Delivery Review]

Authors
C Eng;E Chen;J Rogers;M Lewis;J Strosberg;R Thota;S Krishnamurthi;P Oberstein;R Govindarajan;G Buchschacher;S Patel;D Sohal;T Al-Toubah;P Philip;NA Dasari;H Kennecke;S Stein
Journal / Conference
JCO Oncology Practice
Year
2021
Research Committee(s)
Cancer Care Delivery
PMID
PMID33534616
PMC
PMC8791825

A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficiency (HRRD) Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study S1400G)

Authors
T Owonikoko;M Redman;L Byers;F Hirsch;P Mack;L Schwartz;J Bradley;T Stinchcombe;N Lleighl;T Al Baghdadi;P Lara;J Miao;K Kelly;S Ramalingam;R Herbst;V Papadimitrakopoulou;D Gandara
Journal / Conference
Clinical Lung Cancer May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10.
Year
2021
Research Committee(s)
Lung
PMID
PMID33583720
PMC
PMC8637652
Study Number(s)
S1400G

A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)

Authors
T Flaig;C Tangen;S Daneshmand;A Alva;S Lerner;M Lucia;D McConkey;D Theodorescu;A Goldkorn;M Milowsky;R Bangs;G MacVicor;B Bastos;J Fowles;D Gustafson;M Plets;I Thompson
Journal / Conference
Clinical Cancer Research May 1;27(9):2435-2441; Feb 10;clincanres.2409.2020. doi: 10.1158/1078-0432.CCR-20-2409. Online ahead of print
Year
2021
Research Committee(s)
Genitourinary
PMID
PMID33568346
PMC
PMC8219246
Study Number(s)
S1314